Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of XH-S002 in Healthy Volunteers
NCT06204419Phase 1Recruiting
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing XH-S002 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single ascending doses and Safety and tolerability of multiple ascending doses. Started Dec 2023; status: recruiting.
02
Drugs
XH-S002
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06204419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204419.